

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed for [] Preview Go Clear

Limits Preview/Index **History** Clipboard Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Search

Most Recent Queries

Time Result

#7 Search #1 and #4

17:01:29 1

#6 Search acute coronary events

17:01:19 4653

#3 Search #1 and #2

16:59:47 42

#2 Search atherosclerosis

16:58:01 94970

#1 Search (pla-2 or pla2) and inhibitors

16:57:50 3832

Clear History



Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Oct 12 2005 11:14:01

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display Show Sort by Send to

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

☐ 1: Curr Opin Pharmacol. 2001 Apr;1(2):121-5.

[Related Articles, Links](#)

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target.

Macphee CH.

Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK. Colin_H_Macphee@sbphrd.com

The recognition that atherosclerosis represents an inflammatory disease has begun to shift interest towards novel therapies that could specifically target the underlying inflammatory component of atherogenesis. Like low-density lipoprotein, an ideal new drug target would be a modifiable plasma risk factor that not only reflects the ongoing inflammatory process but also actively promotes it. Lipoprotein-associated phospholipase A2, also known as platelet-activating factor acetylhydrolase, is a new risk factor that may have the potential to fulfil these requirements.

Publication Types:



- [Review](#)
- [Review, Tutorial](#)

PMID: 11714085 [PubMed - indexed for MEDLINE]

Display Show Sort by Send to

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 12 2005 11:14:01

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display 20

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

☐ 1: Farmaco. 2001 Jan-Feb;56(1-2):45-50.

[Related Articles, Links](#)

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy.

Leach CA, Hickey DM, Ife RJ, Macphee CH, Smith SA, Tew DG.

Glaxo SmithKline, New Frontiers Science Park, Harlow, Essex, UK. colin_leach-1@sbphrd.com

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a serine lipase that is associated with low density lipoprotein (LDL) in human plasma. Substrates include oxidised phosphatidylcholine (PC), which is hydrolysed by Lp-PLA2 to lyso-PC and oxidised fatty acids. Both products are bioactive and proinflammatory, and implicated in monocyte infiltration into the developing plaque, deposition of foam cells, and plaque progression and instability. Lp-PLA2 has recently been shown to be a risk factor for coronary events in previously asymptomatic, hypercholesterolaemic men. A series of azetidinones was designed as potent and selective inhibitors of this enzyme; SB-222657 inhibited release of the chemotactic cleavage products from oxidised LDL, and SB-244323 reduced atherosclerotic plaque development in a 3 month rabbit study. A series of pyrimidones has been designed from a screening hit, and nanomolar inhibitors identified. Oral efficacy in inhibiting plasma Lp-PLA2 in rabbits has been demonstrated with a variety of structural classes.

PMID: 11347966 [PubMed - indexed for MEDLINE]

Display 20

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 12 2005 11:14:01